Subgroups of the BENEFIT study: Risk of developing MS and treatment effect of interferon beta-1b
- 15 November 2007
- journal article
- research article
- Published by Springer Nature in Zeitschrift für Neurologie
- Vol. 255 (4) , 480-487
- https://doi.org/10.1007/s00415-007-0733-2
Abstract
The BENEFIT study examined interferon beta (IFNB)-1b treatment in patients with clinically isolated syndrome (CIS) and ≥ 2 clinically silent brain MRI lesions.Keywords
This publication has 23 references indexed in Scilit:
- Treatment with interferon beta-1b delays conversion to clinically definite and McDonald MS in patients with clinically isolated syndromesNeurology, 2006
- MRI T2 lesion burden in multiple sclerosisNeurology, 2006
- Predictors of relapse rate in MS clinical trialsNeurology, 2005
- Is optic neuritis more benign than other first attacks in multiple sclerosis?Annals of Neurology, 2005
- Validation of diagnostic magnetic resonance imaging criteria for multiple sclerosis and response to interferon β1aAnnals of Neurology, 2003
- Intramuscular Interferon Beta-1A Therapy Initiated during a First Demyelinating Event in Multiple SclerosisNew England Journal of Medicine, 2000
- Interferon beta‐1b is effective in relapsing‐remitting multiple sclerosisNeurology, 1993
- Interferon beta‐1b is effective in relapsing‐remitting multiple sclerosisNeurology, 1993
- A Randomized, Controlled Trial of Corticosteroids in the Treatment of Acute Optic NeuritisNew England Journal of Medicine, 1992
- New diagnostic criteria for multiple sclerosis: Guidelines for research protocolsAnnals of Neurology, 1983